NCT01211483 - Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer | Biotech Hunter

Enrollment

222

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

October 31, 2013

Study Completion Date

November 23, 2013

Conditions

NSCLC (Advanced Non-small Cell Lung Cancer)

Interventions

DRUG

U3-1287

Liquid 70 mg/mL for IV infusion at high dose or low dose

DRUG

Erlotinib

Tablet 150 mg for oral administration

DRUG

Placebo

Placebo liquid matching U3-1287 for IV infusion

Trial Locations (52)

85258

TRM - Oncology Research Associates, PLLC, d/b/a Pinnacle Oncology Hematology, Scottsdale

Unknown

Glendale

Anaheim

Encinitas

La Verne

Los Angeles

Orlando

Atlanta

Joliet

Evansville

Baton Rouge

Detroit

The Bronx

York

Graz

Innsbruck

Ghent

Liège

Plovdiv

Sofia

Essen

Frankfurt am Main

Freiburg im Breisgau

Gauting

Halle

Hamburg

Herne

Löwenstein

Mainz

Tübingen

Budapest

Pécs

Petah Tikva

Tel Aviv

Tel Litwinsky

Lido di Camaiore

Piacenza

Pisa

Reggio Emilia

Kaunas

Vilnius

Suceava

Târgu Mureş

Golnik

Dnipropetrovsk

Donetsk

Ivano-Frankivsk

Kharkiv

Sumy

Uzhhorod

London

Metropolitan Borough of Wirral